• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Kiniksa Pharmaceuticals International plc

    10/31/25 11:04:58 AM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KNSA alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 6)


    Kiniksa Pharmaceuticals International Plc

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    G52694109

    (CUSIP Number)


    09/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    G52694109


    1Names of Reporting Persons

    The Vanguard Group
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    PENNSYLVANIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    34,807.00
    7Sole Dispositive Power

    3,004,905.00
    8Shared Dispositive Power

    58,230.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,063,135.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.04 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Kiniksa Pharmaceuticals International Plc
    (b)Address of issuer's principal executive offices:

    100 Hayden Avenue, Lexington, MA, 02421
    Item 2. 
    (a)Name of person filing:

    The Vanguard Group
    (b)Address or principal business office or, if none, residence:

    100 Vanguard Blvd., Malvern, PA 19355
    (c)Citizenship:

    PA
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    G52694109
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    3063135
    (b)Percent of class:

    7.04  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    34807

     (iii) Sole power to dispose or to direct the disposition of:

    3004905

     (iv) Shared power to dispose or to direct the disposition of:

    58230

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5%.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    The Vanguard Group
     
    Signature:Ashley Grim
    Name/Title:Head of Global Fund Administration
    Date:10/31/2025
    Get the next $KNSA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KNSA

    DatePrice TargetRatingAnalyst
    9/29/2025$60.00Buy
    TD Cowen
    3/13/2025$40.00Buy
    Citigroup
    9/13/2024$40.00Buy
    Jefferies
    5/3/2024$34.00Overweight
    Wells Fargo
    12/29/2021$37.00 → $34.00Buy
    B of A Securities
    More analyst ratings

    $KNSA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TD Cowen initiated coverage on Kiniksa Pharmaceuticals with a new price target

    TD Cowen initiated coverage of Kiniksa Pharmaceuticals with a rating of Buy and set a new price target of $60.00

    9/29/25 9:58:02 AM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citigroup initiated coverage on Kiniksa Pharmaceuticals with a new price target

    Citigroup initiated coverage of Kiniksa Pharmaceuticals with a rating of Buy and set a new price target of $40.00

    3/13/25 7:43:42 AM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies initiated coverage on Kiniksa Pharmaceuticals with a new price target

    Jefferies initiated coverage of Kiniksa Pharmaceuticals with a rating of Buy and set a new price target of $40.00

    9/13/24 7:34:05 AM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KNSA
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Kiniksa Pharmaceuticals International plc

    SCHEDULE 13G/A - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)

    10/31/25 11:04:58 AM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Kiniksa Pharmaceuticals International plc

    10-Q - Kiniksa Pharmaceuticals International, plc (0001730430) (Filer)

    10/28/25 4:15:57 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kiniksa Pharmaceuticals International plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Kiniksa Pharmaceuticals International, plc (0001730430) (Filer)

    10/28/25 7:39:36 AM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KNSA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution

    – ARCALYST® (rilonacept) Q3 2025 net product revenue of $180.9 million, representing 61% year-over-year growth –– ARCALYST 2025 expected net product revenue raised to $670 - $675 million –– KPL-387 granted Orphan Drug Designation for the treatment of pericarditis – – Cash balance increased by $44.3 million in Q3 2025 to $352.1 million – – Conference call and webcast scheduled for 8:30 am ET today – LONDON, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, today reported third quarter 202

    10/28/25 7:30:00 AM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kiniksa Pharmaceuticals to Report Third Quarter 2025 Financial Results on October 28, 2025

    LONDON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 28, 2025 at 8:30 a.m. Eastern Time to report its third quarter 2025 financial results and recent portfolio execution. A live webcast will be accessible through the Investors & Media section of the company's website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and re

    10/23/25 4:01:00 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kiniksa Pharmaceuticals Announces U.S. Orphan Drug Designation for KPL-387 for the Treatment of Pericarditis

    LONDON, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to KPL-387 for the treatment of pericarditis, which includes recurrent pericarditis. KPL-387 is an independently developed monoclonal antibody that binds human interleukin-1 receptor 1 (IL-1R1), inhibiting the signaling activity of the cytokines interleukin-1α (IL-1α) and interleukin-1β (IL-1β). "We are pleased to announce that yesterday t

    10/17/25 8:00:00 AM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KNSA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF MEDICAL OFFICER Paolini John F. exercised 82,542 units of Class A Ordinary Share at a strike of $6.60 and sold $3,065,610 worth of Class A Ordinary Share (82,542 units at $37.14) (SEC Form 4)

    4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)

    11/4/25 4:36:17 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF FINANCIAL OFFICER Ragosa Mark exercised 100 units of Class A Ordinary Share at a strike of $30.93 and sold $4,100 worth of Class A Ordinary Share (100 units at $41.00) (SEC Form 4)

    4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)

    10/30/25 4:47:06 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHAIRMAN & CEO Patel Sanj K exercised 257,969 units of Class A Ordinary Share at a strike of $3.80 and sold $10,023,532 worth of Class A Ordinary Share (257,969 units at $38.86) (SEC Form 4)

    4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)

    10/22/25 5:09:09 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KNSA
    Financials

    Live finance-specific insights

    View All

    Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution

    – ARCALYST® (rilonacept) Q3 2025 net product revenue of $180.9 million, representing 61% year-over-year growth –– ARCALYST 2025 expected net product revenue raised to $670 - $675 million –– KPL-387 granted Orphan Drug Designation for the treatment of pericarditis – – Cash balance increased by $44.3 million in Q3 2025 to $352.1 million – – Conference call and webcast scheduled for 8:30 am ET today – LONDON, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, today reported third quarter 202

    10/28/25 7:30:00 AM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kiniksa Pharmaceuticals to Report Third Quarter 2025 Financial Results on October 28, 2025

    LONDON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 28, 2025 at 8:30 a.m. Eastern Time to report its third quarter 2025 financial results and recent portfolio execution. A live webcast will be accessible through the Investors & Media section of the company's website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and re

    10/23/25 4:01:00 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution

    – ARCALYST® (rilonacept) Q2 2025 net product revenue of $156.8 million, representing 52% year-over-year growth –– ARCALYST 2025 expected net product revenue increased to $625 - $640 million –– KPL-387 Phase 2/3 clinical trial in recurrent pericarditis initiated; Phase 2 data expected in 2H 2026 –– Cash balance increased by $39.4 million in Q2 2025 to $307.8 million –– Conference call and webcast scheduled for 8:30 am ET today – LONDON, July 29, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, today

    7/29/25 7:30:00 AM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KNSA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Kiniksa Pharmaceuticals International plc

    SC 13G/A - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)

    11/14/24 4:32:31 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Kiniksa Pharmaceuticals International plc

    SC 13G/A - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)

    11/14/24 4:15:22 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Kiniksa Pharmaceuticals International plc

    SC 13G/A - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)

    11/13/24 4:30:25 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care